Placeholder Banner

Sarbanes-Oxley in Financial Services Compromise: Sarbanes-Oxley 404(b) Legislative Text in the Wall Street Reform and Consumer Protection Act of 2009

March 10, 2016

BIO advocated for a provision in financial services reform that would ease regulatory burdens for small public biotechnology companies. The provision would permanently exempt companies with market capitalizations of $75 million or less from Section 404(b) of the Sarbanes-Oxley Act of 2002 (SOX). BIO has advocated strongly on behalf of this provision, which would become law if the current compromise passes both chambers of Congress. The House passed the financial regulatory reform compromise on June 30 by a vote of 237-192 and the Senate is expected to vote on the measure after the July 4th recess.

Download Full Comments Below
404(b) Perm Exemption House-Senate Comprise
Read the document
Discover More
BIO and BIO members are urging lawmakers to enact a short-term extension of the MCM-PRV program while Congress is waiting to address a full reauthorization with PAHPA.
BIO response to Federal Trade Commission request for comment on the agency's Guides for the Use of Environmental Marketing Claims (Green Guides)
BIO has submitted comments to the Office of Science & Technology Policy on how regulations underpinning the Coordinated Framework for the Regulation of Biotechnology can better facilitate the use of biotechnology to stimulate the economy…